Skip to main content

Advertisement

SpringerLink
Log in

Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Autoantibodies are important in the diagnosis of dermatomyositis. They can be divided in two different groups: myositis-associated autoantibodies (MAA) prevailing in overlap syndromes, and myositis-specific autoantibodies (MSA), with diagnostic specificity exceeding 90%. Our purpose was to detect retrospectively the prevalence of the most common MSAs in a group of 19 adult DM patients (13 women, 6 men). A severe DM (SDM), with extensive cutaneous and muscular manifestations, dysphagia, and sometimes pneumopathy, was detected in ten cases. Three patients had a mild DM (MDM), with little muscle and skin impairment, and a short course. Four patients suffered from amyopathic DM (ADM), two from paraneoplastic DM (PDM). Each serum was tested for ANA, ENA, MAAs, MSAs. Myositis-specific autoantibodies were detected in 15 cases. The most frequent was anti-TIF1γ, associated with SDM or PDM in four out of seven cases. Anti-MDA5 antibodies were recorded in a SDM and in a ADM with lung fibrosis. Anti-Mi2 and anti-SRP antibodies were both detected in a MDM and in a SDM, whereas anti-SAE1 in a amyopathic form. Other antibodies (anti-NXP2, -Jo1, -PL7, -PL12, -OJ) were found in single patients with SDM. Our series confirmed that specific autoantibodies could be helpful to classify different clinical subsets, particularly in the case of paraneoplastic forms or association with pneumopathy. Moreover, they can help in predicting the disease evolution and influence therapeutic strategies. A greater number of cases should be useful to highlight the clinical and pathogenic role of these antibodies, and develop a homogeneous protocol for diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allenbach Y, Benveniste O (2014) Autoantibody profile in myositis. Rev Med Interne 35:437–443

    Article  CAS  PubMed  Google Scholar 

  2. Andersen P (1977) Correlation of smooth-muscle and nuclear antibodies in normal subjects. Clin Exp Immunol 27:74–77

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Anyanwu CO, Fiorentino D, Chung L, Dzuong C, Wang Y, Okawa J et al (2015) Validation of the cutaneous dermatomyositis disease area and severity index (CDASI): characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol 173:969–974

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Benveniste O, Drouot L, Jouen F, Charuel JL, Bloch-Queyrat C, Behin A et al (2011) Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63:1961–1971

    Article  CAS  PubMed  Google Scholar 

  5. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N (2007) Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 56:3132–3137

    Article  CAS  PubMed  Google Scholar 

  6. Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23

    Article  CAS  PubMed  Google Scholar 

  7. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG et al (2009) Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 68:1621–1625

    Article  CAS  PubMed  Google Scholar 

  8. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (2014) Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 13:1211–1219

    Article  CAS  PubMed  Google Scholar 

  9. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    Article  CAS  PubMed  Google Scholar 

  10. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407

    Article  CAS  PubMed  Google Scholar 

  11. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC (2006) Update on idiopathic inflammatory myopathies. Autoimmunity 39:161–170

    Article  CAS  PubMed  Google Scholar 

  12. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60:116–123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Callander J, Robson Y, Ingram J, Piguet V (2016) Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. Br J Dermatol. doi:10.1111/bjd.14726

    Google Scholar 

  14. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 64:1602–1610

    Article  Google Scholar 

  15. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M et al (2012) Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 14:R97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S et al (2012) A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) 91:220–228

    Article  Google Scholar 

  17. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345–1349

    Article  PubMed  PubMed Central  Google Scholar 

  18. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL (2010) A novel autoantibody recognizing 200- and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62:2757–2766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 2003(362):971–982

    Article  Google Scholar 

  20. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV (2009) Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 36:2547–2551

    Article  CAS  PubMed  Google Scholar 

  21. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65:25–34

    Article  PubMed  PubMed Central  Google Scholar 

  22. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65:2954–2962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 72:449–455

    Article  PubMed  PubMed Central  Google Scholar 

  24. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522

    Article  CAS  PubMed  Google Scholar 

  25. Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F et al (2013) Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72:151–153

    Article  PubMed  Google Scholar 

  26. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L et al (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15:335

    Article  PubMed  Google Scholar 

  27. Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A (2014) Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 5:69–75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF et al (2005) Anti-Mi-2 antibodies. Autoimmunity 38:79–83

    Article  CAS  PubMed  Google Scholar 

  29. Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48:607–612

    Article  CAS  Google Scholar 

  30. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 1(47):391–398

    Article  Google Scholar 

  31. Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J et al (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L et al (2014) The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 48–49:122–127

    Article  PubMed  Google Scholar 

  33. Kalus A (2015) Rheumatologic skin disease. Med Clin N Am 99:1287–1303

    Article  PubMed  Google Scholar 

  34. Komura K, Fujimoto M, Matsushita T, Kaji K, Kondo M, Hirano T et al (2005) Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci 40:215–217

    Article  CAS  PubMed  Google Scholar 

  35. Lazarou IN, Guerne PA (2013) Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 40:550–564

    Article  CAS  PubMed  Google Scholar 

  36. Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M et al (2014) The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 13:883–891

    Article  CAS  PubMed  Google Scholar 

  37. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70:360–374

    Article  CAS  Google Scholar 

  38. Luo YB, Mastaglia FL (2015) Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 1852:622–632

    Article  CAS  PubMed  Google Scholar 

  39. Mammen AL (2011) Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7:343–354

    Article  CAS  PubMed  Google Scholar 

  40. Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14:275–285

    Article  CAS  PubMed  Google Scholar 

  41. Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin N Am 28:723–741

    Article  Google Scholar 

  42. Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14:264–274

    Article  CAS  PubMed  Google Scholar 

  43. Moghadam-Kia S, Aggarwal R, Oddis CV (2015) Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol 11:1265–1275

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 46:279–284

    Article  CAS  PubMed  Google Scholar 

  45. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K (2011) Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 13:R214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Oddis CV, Conte CG, Steen VD, Medsger TA Jr (1990) Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol 17:1329–1334

    CAS  PubMed  Google Scholar 

  47. Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ (1997) Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 109:32–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathicdermatomyositis. Arthritis Rheum 52:1571–1576

    Article  CAS  PubMed  Google Scholar 

  49. Smoyer-Tomic KE, Amato AA, Fernandes AW (2012) Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 13:103

    Article  PubMed  PubMed Central  Google Scholar 

  50. Tansley SL, Betteridge ZE, McHugh NJ (2013) The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 25:772–777

    Article  CAS  PubMed  Google Scholar 

  51. Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33:1361–1370

    Article  CAS  PubMed  Google Scholar 

  52. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP et al (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54:3682–3689

    Article  CAS  PubMed  Google Scholar 

  53. Targoff IN, Reichlin M (1985) The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 28:796–803

    Article  CAS  PubMed  Google Scholar 

  54. Targoff IN (1992) Autoantibodies in polymyositis. Rheum Dis Clin N Am 18:455–482

    CAS  Google Scholar 

  55. Venables PJ (1997) Antibodies to Jo-1 and Ro-52: why do they go together? Clin Exp Immunol 109:403–405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Walter P, Blobel G (1982) Signal recognition particle contains a 7S RNA essential for protein translocation across the endoplasmic reticulum. Nature 299:691–698

    Article  CAS  PubMed  Google Scholar 

  57. Whelan BR, Isenberg DA (2009) Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford) 48:594–595

    Article  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Di.S.Sal. Section of Dermatology, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Via Pastore 1, 16132, Genoa, Italy

      Giulia Merlo, Andrea Clapasson, Emanuele Cozzani, Luigi Sanna, Martina Burlando & Aurora Parodi

    2. Autoimmunity Unit, Department of Internal Medicine (DIMI), University of Genoa, Viale Benedetto XV, 16132, Genoa, Italy

      Andrea Clapasson, Giampaola Pesce & Marcello Bagnasco

    Authors
    1. Giulia Merlo
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Andrea Clapasson
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Emanuele Cozzani
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Luigi Sanna
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Giampaola Pesce
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Marcello Bagnasco
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Martina Burlando
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Aurora Parodi
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Emanuele Cozzani.

    Ethics declarations

    Funding

    This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Additional information

    G. Merlo and A. Clapasson contributed equally to this manuscript, respectively, for the medical and laboratory section.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Merlo, G., Clapasson, A., Cozzani, E. et al. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets. Arch Dermatol Res 309, 87–95 (2017). https://doi.org/10.1007/s00403-016-1704-1

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00403-016-1704-1

    Keywords

    Search

    Navigation